Professor Sherene Loi
Peter MacCallum Cancer Center / University of Melbourne
I am a Medical Oncologist specialized in breast cancer treatment as well as a clinician scientist with expertise in genomics, immunology and drug development. My work is focused on developing new therapeutic approaches that may improve outcomes of breast cancer patients. After completing Medical Oncology specialist clinical training in 2003, I undertook a PhD and postdoctoral studies at the Institut Jules Bordet in Brussels, Belgium (2003-2012). In 2013, I returned to head the newly created Translational Breast Cancer Genomics and Therapeutics laboratory at the Peter MacCallum Cancer Centre, Melbourne, as well as Consultant Medical Oncologist in the Breast Service and head of the Breast Cancer Clinical Trials Unit. I am recognised internationally as a leading clinician scientist whose work has led to new insights into the immunology field in breast cancer. As a result of my research, I lead a number of international breast cancer clinical trials in immunotherapy. To date, I have published over 220 peer-reviewed research articles with a lifetime H index of 74. My recent work has been highly influential with 27,250 total citations and 20,369 (74%) within the past 5 years (Google Scholar). I am a Board Director as well as a member of the Scientific Advisory Committee of the Australia New Zealand Breast Cancer Trials Group (BCT Australia/NZ), which is the largest breast cancer clinical trials cooperative group in Australia. I Co-Chair the Scientific Executive Committee and the Translational Working Group of the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland which conducts academic global breast cancer clinical trials in over 16 countries. I am the current holder of the Inaugural National Breast Cancer Foundation (NBCF) of Australia Endowed Chair and a research fellow of the Breast Cancer Research Foundation (BCRF), New York. I am also on the Scientific Committee for Breast Cancer for the American Society of Clinical Oncology (ASCO).